Unknown

Dataset Information

0

Safety, tolerability, pharmacokinetics, and pharmacodynamics of novel glucokinase activator HMS5552: results from a first-in-human single ascending dose study.


ABSTRACT:

Background

HMS5552, a novel fourth-generation glucokinase (GK) activator, has demonstrated promising effects on glycemic control in preclinical models of type 2 diabetes. This single ascending dose study was conducted to investigate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of HMS5552 during its first-in-human exposure.

Methods

Sixty healthy subjects were enrolled. In each of six dose-cohorts (5, 10, 15, 25, 35, and 50 mg), ten subjects were randomized with eight subjects receiving the same cohort-dose of HMS5552 and two receiving placebo. Plasma HMS5552 exposure, glucose, and insulin were measured repeatedly during fasting and after a standardized meal. Assessment included safety, PK, and PD endpoints.

Results

HMS5552 showed dose-proportional increases in area under the curve 0 to the last quantifiable concentration (AUC0-t) and maximum plasma concentration (Cmax). Slopes estimated by linear regression for AUC0-t and Cmax were ~1.0 (0.932 and 0.933, respectively). Geometric mean elimination half-life ranged from 4.48 to 7.51 hours and apparent clearance ranged from 11.5 to 13.1 L/h across all doses. No significant sex effect was observed in PK parameters. HMS5552 also demonstrated dose-related PD responses in terms of maximum glucose change from baseline (%) and mean glucose area under effect curve 0-4 hours change from baseline (%) (P<0.001). Fifteen adverse events were reported by nine subjects (ten with HMS5552 and five with the placebo). All adverse events were mild in intensity and resolved without any treatment.

Conclusion

This first-in-human single ascending dose study provided predicted PK of HMS5552 with dose-proportional increases in AUC0-t and Cmax, as well as dose-related glucose-lowering effects over the range of 5-50 mg in healthy subjects. HMS5552 at doses up to 50 mg in healthy subjects was safe and well-tolerated.

SUBMITTER: Xu H 

PROVIDER: S-EPMC4869670 | biostudies-literature | 2016

REPOSITORIES: biostudies-literature

altmetric image

Publications

Safety, tolerability, pharmacokinetics, and pharmacodynamics of novel glucokinase activator HMS5552: results from a first-in-human single ascending dose study.

Xu Hongrong H   Sheng Lei L   Chen Weili W   Yuan Fei F   Yang Mengjie M   Li Hui H   Li Xuening X   Choi John J   Zhao Guiyu G   Hu Tianxin T   Li Yongguo Y   Zhang Yi Y   Chen Li L  

Drug design, development and therapy 20160509


<h4>Background</h4>HMS5552, a novel fourth-generation glucokinase (GK) activator, has demonstrated promising effects on glycemic control in preclinical models of type 2 diabetes. This single ascending dose study was conducted to investigate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of HMS5552 during its first-in-human exposure.<h4>Methods</h4>Sixty healthy subjects were enrolled. In each of six dose-cohorts (5, 10, 15, 25, 35, and 50 mg), ten subjects were random  ...[more]

Similar Datasets

| S-EPMC10087697 | biostudies-literature
| S-EPMC9464004 | biostudies-literature
| S-EPMC9338184 | biostudies-literature
| S-EPMC7548281 | biostudies-literature
2023-07-24 | GSE237965 | GEO
| S-EPMC8246954 | biostudies-literature
| S-EPMC7163368 | biostudies-literature
| S-EPMC11465679 | biostudies-literature
| S-EPMC9969340 | biostudies-literature
| S-EPMC11449976 | biostudies-literature